Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing the Ability of the T-SPOT®.TB Test to Identify Those at Risk of Active Mycobacterium Tuberculosis Infection Using the Normalized Tuberculosis (TB) Specific Lymphocyte Response.

NCT03973970 is registered in ClinicalTrials.gov with Oxford Immunotec as lead sponsor.

NCT NCT03973970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03973970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing the Ability of the T-SPOT®.TB Test to Identify Those at Risk of Active Mycobacterium Tuberculosis Infection Using the Normalized Tuberculosis (TB) Specific Lymphocyte Response.
Lead sponsor
Oxford Immunotec
Phase
Observational
Overall status
Completed
Start date
September 23, 2019
Completion date
June 30, 2020
Enrollment
201 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis